Drug intelligence / Profile preview

TJ-062

Development stage
Preclinical
Lead developer
Tuojie Biotech
Modality
Small Molecules
Administration
Oral
01

Overview

TJ-062, also known as bofu-tsusho-san or TJ-62, is a traditional Japanese Kampo medicine formulation under investigation for its anti-obesity and thermogenic effects. It is a small molecule drug composed of multiple herbal extracts. Preclinical studies in mice have shown that TJ-062 activates brown adipose tissue (BAT) thermogenesis and inhibits phosphodiesterase activity, leading to increased energy expenditure and reduced body weight without affecting food intake. The mechanism appears to involve enhanced GDP binding in BAT and inhibition of phosphodiesterase similar to caffeine. The product contains active components such as 1-E (likely ephedrine-type alkaloid) and d-PE (possibly p-synephrine or related compound), but the full composition includes several herbal extracts typical of Kampo formulas[1]. Developed by Shanghai Tuojie Biotechnology.

Brand names
TJ-062TJ062TJ 062
Other names
bofu-tsusho-sanTJ-62TJ62TJ 62
02

Targets

PDE (Phosphodiesterase family)

Beyond the preview

Go deeper on TJ-062.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on TJ-062.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call